Information Technology

Instem plc

  • Market Cap (£m) #N/A
  • Listing AIM

Analysts

Company Descriptions

Instem is a leading provider of IT solutions & services to the life sciences market. Instem provides advanced IT solutions to the global health and life sciences community which improves the productivity of their processes in the discovery and development of new drugs, therapies and products.

Investment Summary

Instem came to market in 2010 with a compelling story based on dominance of a niche market, good recurring revenues and strong cash generation. In our view, the group has a strong track record of delivery, and the favourable market backdrop gives further confidence in the growth story.

Company Management Team

  • Phil Reason

    Chief Executive Officer

    Phil is an experienced chief executive who has developed a number of IT businesses in the life sciences and nuclear industries, both organically and through acquisition. Phil joined the former parent Company, Instem Limited in 1982 and was appointed Managing Director of the Life Sciences division in 1995 and Chief Executive Officer of Instem LSS Limited on the demerger from Instem Limited. Given the importance of the North American market to Instem’s organic and acquisitive growth, Phil relocated from the UK to the US in 2003 and established a new headquarters in the Philadelphia area. Phil previously ran Instem Limited’s Nuclear and Laboratory Information Management Systems integration businesses.

  • Nigel Goldsmith

    Chief Financial Officer

    Nigel, who joined Instem in November 2011, has a wealth of experience in senior financial roles, at both public and private companies within the pharmaceutical industry. After qualifying as a Chartered Accountant, Nigel spent over nine years at KPMG prior to moving into industry. Nigel was Finance Director for three years at AIM listed, pharmaceutical and medical devices company, IS Pharma plc. He also spent a seven-year tenure as CFO at Almedica International Inc, a privately held supplier of clinical trial materials to the pharmaceutical and biotech industry in Europe and the US and two years as European Controller for the sales and marketing division of laboratory equipment manufacturer, Life Sciences International plc.